{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:36:54Z","timestamp":1791272214829,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"7-8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s00508-014-0503-y","type":"journal-article","created":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T09:31:33Z","timestamp":1393925493000},"page":"189-194","source":"Crossref","is-referenced-by-count":12,"title":["Reporting bias in trials of volume resuscitation with hydroxyethyl starch","Publikationsbias in klinischen Studien zur Volumentherapie mit Hydroxyethylst\u00e4rke"],"prefix":"10.1007","volume":"126","author":[{"given":"Christian J.","family":"Wiedermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,5]]},"reference":[{"key":"503_CR1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1745-6215-11-37","volume":"11","author":"N McGauran","year":"2010","unstructured":"McGauran N, Wieseler B, Kreis J, Sch\u00fcler YB, K\u00f6lsch H, Kaiser T. Reporting bias in medical research\u2014a narrative review. Trials. 2010;11:37.","journal-title":"Trials"},{"key":"503_CR2","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0140-6736(91)90201-Y","volume":"337","author":"PJ Easterbrook","year":"1991","unstructured":"Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867\u201372.","journal-title":"Lancet"},{"key":"503_CR3","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jama.1992.03480030052036","volume":"267","author":"K Dickersin","year":"1992","unstructured":"Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results: follow-up of applications submitted to two institutional review boards. JAMA. 1992;267:374\u20138.","journal-title":"JAMA"},{"key":"503_CR4","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/bmj.315.7109.640","volume":"315","author":"JM Stern","year":"1997","unstructured":"Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ. 1997;315:640\u20135.","journal-title":"BMJ"},{"key":"503_CR5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/bmj.38488.385995.8F","volume":"331","author":"E Decullier","year":"2005","unstructured":"Decullier E, Lheritier V, Chapuis F. Fate of biomedical research protocols and publication bias in France: retrospective cohort study. BMJ. 2005;331:19\u201324.","journal-title":"BMJ"},{"key":"503_CR6","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1136\/jme.2008.024521","volume":"34","author":"A Blumle","year":"2008","unstructured":"Blumle A, Antes G, Schumacher M, Just H, Von Elm E. Clinical research projects at a German medical faculty: follow-up from ethical approval to publication and citation by others. J Med Ethics. 2008;34:e20.","journal-title":"J Med Ethics"},{"key":"503_CR7","doi-asserted-by":"crossref","first-page":"e3081","DOI":"10.1371\/journal.pone.0003081","volume":"38","author":"K Dwan","year":"2008","unstructured":"Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E, et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One. 2008;38:e3081.","journal-title":"PLoS One"},{"key":"503_CR8","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/bmj.326.7400.1171","volume":"326","author":"H Melander","year":"2003","unstructured":"Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine\u2014selective reporting from studies sponsored by pharmaceutical industry; review of studies in new drug applications. BMJ. 2003;326:1171\u20133.","journal-title":"BMJ"},{"key":"503_CR9","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1001\/jama.291.20.2457","volume":"291","author":"AW Chan","year":"2004","unstructured":"Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004;291:2457\u201365.","journal-title":"JAMA"},{"key":"503_CR10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jama.285.4.437","volume":"285","author":"JP Ioannidis","year":"2001","unstructured":"Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285:437\u201343.","journal-title":"JAMA"},{"key":"503_CR11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385\u201396.","journal-title":"Drug Saf"},{"key":"503_CR12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/pds.979","volume":"14","author":"J Bonhoeffer","year":"2005","unstructured":"Bonhoeffer J, Zumbrunn B, Heininger U. Reporting of vaccine safety data in publications: systematic review. Pharmacoepidemiol Drug Saf. 2005;14:101\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"503_CR13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1472-6904-1-3","volume":"1","author":"YK Loke","year":"2001","unstructured":"Loke YK, Derry S. Reporting of adverse drug reactions in randomised controlled trials: a systematic survey. BMC Clin Pharmacol. 2001;1:3.","journal-title":"BMC Clin Pharmacol"},{"key":"503_CR14","first-page":"562","volume":"77","author":"No authors listed.","year":"2011","unstructured":"No authors listed. Editors-in-Chief statement regarding published clinical trials conducted without IRB approval by Joachim Boldt. Minerva Anestesiol. 2011;77:562\u20133.","journal-title":"Minerva Anestesiol"},{"key":"503_CR15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1213\/ANE.0b013e31820ad3b7","volume":"112","author":"SL Shafer","year":"2011","unstructured":"Shafer SL. Shadow of doubt. Anesth Analg. 2011;112:498\u2013500.","journal-title":"Anesth Analg"},{"key":"503_CR16","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1001\/jama.2013.430","volume":"309","author":"R Zarychanski","year":"2013","unstructured":"Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, Fergusson DA. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA. 2013;309:678\u201388.","journal-title":"JAMA"},{"key":"503_CR17","first-page":"CD007594","volume":"7","author":"TC Mutter","year":"2013","unstructured":"Mutter TC, Ruth CA, Dart AB. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev. 2013;7:CD007594.","journal-title":"Cochrane Database Syst Rev"},{"key":"503_CR18","doi-asserted-by":"crossref","first-page":"R166","DOI":"10.1186\/cc12845","volume":"17","author":"P Meybohm","year":"2013","unstructured":"Meybohm P, Van Aken H, De Gasperi A, De Hert S, Della Rocca G, Girbes AR, et al. Re-evaluating currently available data and suggestions for planning randomized controlled studies regarding the use of hydroxyethyl-starch in critically ill patients\u2014a multidisciplinary statement. Crit Care. 2013;17:R166.","journal-title":"Crit Care"},{"key":"503_CR19","doi-asserted-by":"crossref","first-page":"R40","DOI":"10.1186\/cc8920","volume":"14","author":"N Boussekey","year":"2010","unstructured":"Boussekey N, Darmon R, Langlois J, Alfandari S, Devos P, Meybeck A, et al. Resuscitation with low volume hydroxyethylstarch 130\u00a0kDa\/0.4 is not associated with acute kidney injury. Crit Care. 2010;14:R40.","journal-title":"Crit Care"},{"key":"503_CR20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/bja\/aer229","volume":"107","author":"MF James","year":"2011","unstructured":"James MF, Michell WL, Joubert IA, Nicol AJ, Navsaria PH, Gillespie RS. Resuscitation with hydroxyethyl starch improves renal function and lactate clearance in penetrating trauma in a randomized controlled study: the FIRST trial (Fluids in Resuscitation of Severe Trauma). Br J Anaesth. 2011;107:693\u2013702.","journal-title":"Br J Anaesth"},{"key":"503_CR21","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/cc11358","volume":"16","author":"B Guidet","year":"2012","unstructured":"Guidet B, Martinet O, Boulain T, Philippart F, Poussel JF, Maizel J, et al. Assessment of hemodynamic efficacy and safety of 6\u2009% hydroxyethylstarch 130\/0.4 vs. 0.9\u2009% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study. Crit Care. 2012;16:R94.","journal-title":"Crit Care"},{"key":"503_CR22","doi-asserted-by":"crossref","first-page":"R185","DOI":"10.1186\/cc9293","volume":"14","author":"S Finfer","year":"2010","unstructured":"Finfer S, Liu B, Taylor C, Bellomo R, Billot L, Cook D, et al. Resuscitation fluid use in critically ill adults: an international cross-sectional study in 391 intensive care units. Crit Care. 2010;14:R185.","journal-title":"Crit Care"},{"key":"503_CR23","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s00101-013-2220-8","volume":"62","author":"M Rehm","year":"2013","unstructured":"Rehm M. Limited applications for hydroxyethyl starch: background and alternative concepts. Anaesthesist. 2013;62:644\u201355.","journal-title":"Anaesthesist"},{"key":"503_CR24","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1213\/ANE.0b013e31820ad607","volume":"112","author":"CS Hartog","year":"2011","unstructured":"Hartog CS, Kohl M, Reinhart K. A systematic review of third generation hydroyethyl starch (HES 130\/0.4) in resuscitation: safety not adequately addressed. Anesth Analg. 2011;112:635\u201345.","journal-title":"Anesth Analg"},{"key":"503_CR25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00508-004-0237-3","volume":"116","author":"CJ Wiedermann","year":"2004","unstructured":"Wiedermann CJ. Hydroxyethyl starch\u2014can the safety problems be ignored? Wien Klin Wochenschr. 2004;116:583\u201394.","journal-title":"Wien Klin Wochenschr"},{"key":"503_CR26","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archsurg.139.5.552","volume":"193","author":"ME Barron","year":"2004","unstructured":"Barron ME, Wilkes MM, Narvickis RJ. A systematic review of the comparative safety of colloids. Arch Surg. 2004;193:552\u201363.","journal-title":"Arch Surg"},{"key":"503_CR27","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/CCM.0b013e318212096a","volume":"39","author":"O Bayer","year":"2011","unstructured":"Bayer O, Reinhart K, Sakr Y, Kabisch B, Kohl M, Riedemann NC, et al. Renal effects of synthetic colloids and crystalloids in patients with severe sepsis: a prospective sequential comparison. Crit Care Med. 2011;39:1335\u201342.","journal-title":"Crit Care Med"},{"key":"503_CR28","doi-asserted-by":"crossref","unstructured":"St\u00e4nder S, Richter L, Osada N, Metze D. Hydroxyethyl starch-induced pruritus. Clinical characteristics and influence of dose, molecular weight and substitution. Acta Derm Venereol. 2013;93. doi:10.2340\/00015555-1639.","DOI":"10.2340\/00015555-1639"},{"key":"503_CR29","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/S0140-6736(96)07588-5","volume":"14","author":"ML Cittanova","year":"1996","unstructured":"Cittanova ML, Leblanc I, Legendre CH, Mouquet C, Riou B, Coriat P. Effect of hydroxyethyl starch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet. 1996;14:1620\u20132.","journal-title":"Lancet"},{"key":"503_CR30","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1136\/bmj.3.5621.783","volume":"3","author":"TF Solanke","year":"1968","unstructured":"Solanke TF. Clinical trial of 6 per cent hydroxyethyl starch (a new plasma expander). BMJ. 1968;3:783\u20135.","journal-title":"BMJ"},{"key":"503_CR31","first-page":"274","volume":"89","author":"Drug Commission of the German Medical Association","year":"1992","unstructured":"Drug Commission of the German Medical Association. Acute renal failure after infusion of hydroxyethyl starch during haemodilution therapy. Dtsch \u00c4rztebl. 1992;89:274.","journal-title":"Dtsch \u00c4rztebl"},{"key":"503_CR32","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1055\/s-2001-18182","volume":"36","author":"J Boldt","year":"2001","unstructured":"Boldt J. Limited dosage for HES? An\u00e4sthesiol Intensivmed Notfallmed Schmerzther. 2001;36:102\u20133.","journal-title":"An\u00e4sthesiol Intensivmed Notfallmed Schmerzther"},{"key":"503_CR33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/ALN.0b013e3181a7ec82","volume":"111","author":"M Westphal","year":"2009","unstructured":"Westphal M, James MF, Kozek-Langenecker S, Stocker R, Guidet B, Van Aken H. Hydroxyethyl starches: different products different effects. Anesthesiology. 2009;111:187\u2013202.","journal-title":"Anesthesiology"},{"key":"503_CR34","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(00)04211-2","volume":"357","author":"F Schortgen","year":"2001","unstructured":"Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet. 2001;357:911\u20136.","journal-title":"Lancet"},{"key":"503_CR35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa070716","volume":"358","author":"FM Brunkhorst","year":"2008","unstructured":"Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, et al. German competence network sepsis (SepNet). Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125\u201339.","journal-title":"N Engl J Med"},{"key":"503_CR36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00508-011-1532-4","volume":"123","author":"CS Hartog","year":"2011","unstructured":"Hartog CS, Brunkhorst FM, Engel C, Meier-Hellmann A, Ragaller M, Hartog CS, et al. Are renal adverse effects of hydroxyethyl starches merely a consequence of their incorrect use? Wien Klin Wochenschr. 2011;123:145\u201355.","journal-title":"Wien Klin Wochenschr"},{"key":"503_CR37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1056\/NEJMoa1204242","volume":"367","author":"A Perner","year":"2012","unstructured":"Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, \u00c5neman A, et al. Hydroxyethyl starch 130\/0.42 versus Ringer\u2019s acetate in severe sepsis. N Engl J Med. 2012;367:124\u201334.","journal-title":"N Engl J Med"},{"key":"503_CR38","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1056\/NEJMoa1209759","volume":"367","author":"JA Myburgh","year":"2012","unstructured":"Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med. 2012;367:1901\u201311.","journal-title":"N Engl J Med"},{"key":"503_CR39","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s00134-013-2840-0","volume":"39","author":"DJ Gattas","year":"2013","unstructured":"Gattas DJ, Dan A, Myburgh J, Billot L, Lo S, Finfer S, CHEST Management Committee. Fluid resuscitation with 6 % hydroxyethyl starch (130\/0.4 and 130\/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Med. 2013;39:558\u201368.","journal-title":"Intensive Care Med"},{"key":"503_CR40","doi-asserted-by":"crossref","unstructured":"Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, Wetterslev J. Hydroxyethyl starch 130\/0.38\u20130.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ. 2013;346:f839.","DOI":"10.1136\/bmj.f839"},{"key":"503_CR41","first-page":"451","volume":"26","author":"CS Hartog","year":"2013","unstructured":"Hartog CS, Welte T, Schlattmann P, Reinhart K. Volumentherapie mit Hydroxy\u00e4thylst\u00e4rke beim kritisch kranken: eine Neubewertung. Dtsch \u00c4rztebl. 2013;26:451\u20139.","journal-title":"Dtsch \u00c4rztebl"},{"key":"503_CR42","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00134-013-2863-6","volume":"39","author":"A Patel","year":"2013","unstructured":"Patel A, Waheed U, Brett SJ. Randomised trials of 6 % tetrastarch (hydroxyethyl starch 130\/0.4 or 0.42) for severe sepsis reporting mortality: systematic review and meta-analysis. Intensive Care Med. 2013;39:811\u201322.","journal-title":"Intensive Care Med"},{"key":"503_CR43","first-page":"w13747","volume":"143","author":"CJ Wiedermann","year":"2013","unstructured":"Wiedermann CJ, Joannidis M. Increased mortality after infusion of \u201cmodern\u201d hydroxyethyl starch. Schweiz Med Wochenschr. 2013;143:w13747.","journal-title":"Schweiz Med Wochenschr"},{"key":"503_CR44","unstructured":"European Medicines Agency. PRAC recommends suspending marketing authorisations for infusion solutions containing hydroxyethyl starch. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2013\/06\/news_detail_001814.jsp&mid=WC0b01ac058004d5c1 . Accessed 12 Sept 2013."},{"key":"503_CR45","unstructured":"Food and Drug Administration. FDA safety communication: boxed warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethyl starch solutions in some settings. http:\/\/www.fda.gov\/BiologicsBloodVaccines\/SafetyAvailability\/ucm358271.htm . Accessed 12 Sept 2013."},{"key":"503_CR46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1757-7241-21-61","volume":"21","author":"D Chappell","year":"2013","unstructured":"Chappell D, Jacob M. Hydroxyethyl starch\u2014the importance of being earnest. Scand J Trauma Resusc Emerg Med. 2013;21:61.","journal-title":"Scand J Trauma Resusc Emerg Med"},{"key":"503_CR47","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00134-012-2614-0","volume":"38","author":"CS Hartog","year":"2012","unstructured":"Hartog CS, Skupin H, Natanson C, Sun J, Reinhart K. Systematic analysis of hydroxyethyl starch (HES) reviews: proliferation of low-quality reviews overwhelms the results of well-performed meta-analyses. Intensive Care Med. 2012;38:1258\u201371.","journal-title":"Intensive Care Med"},{"key":"503_CR48","unstructured":"Austrian Society of Anaesthesiology, Resuscitation and Intensive Care Medicine (\u00d6GARI). Fluid and volume therapy. http:\/\/www.oegari.at\/web_files\/dateiarchiv\/473\/Information%20Kompakt%20Fl%C3%BCssigkeits-%20und%20Volumentherapie%201.1.pdf . Accessed 12 Sept 2013."},{"key":"503_CR49","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/cc11673","volume":"16","author":"CS Hartog","year":"2012","unstructured":"Hartog CS, Reinhart K. CRYSTMAS study adds to concerns about renal safety and increased mortality in sepsis patients. Crit Care. 2012;16:454.","journal-title":"Crit Care"},{"key":"503_CR50","unstructured":"Food and Drug Administration. Hydroxyethyl starch solutions. FDA safety communication\u2014boxed warning on increased mortality and several renal injury and risk of bleeding. http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm358349.htm . Accessed 12 Sept 2013."},{"key":"503_CR51","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/bja\/aer467","volume":"108","author":"K Reinhart","year":"2012","unstructured":"Reinhart K, Hartog CS. Hydroxyethyl starch in patients with trauma. Br J Anaesth. 2012;108:321\u20132.","journal-title":"Br J Anaesth"},{"key":"503_CR52","unstructured":"ISRCTN Register. A trial of crystalloid versus colloid fluid solutions for the resuscitation of patients with severe injuries. www.controlled-trials.com\/ISRCTN42061860\/42061860 . Accessed 12 Sept 2013."},{"key":"503_CR53","doi-asserted-by":"crossref","first-page":"11914","DOI":"10.1016\/S0140-6736(00)04337-3","volume":"357","author":"D Moher","year":"2001","unstructured":"Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357:11914.","journal-title":"Lancet"},{"key":"503_CR54","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/bja\/aer424","volume":"108","author":"S Finfer","year":"2012","unstructured":"Finfer S. Hydroxyethyl starch in patients with trauma. Br J Anaesth. 2012;108:159\u201360.","journal-title":"Br J Anaesth"},{"key":"503_CR55","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/ALN.0b013e31827e5569","volume":"118","author":"C Martin","year":"2013","unstructured":"Martin C, Jacob M, Vicaut E, Guidet B, Van Aken H, Kurz A. Effect of waxy maize-derived hydroxyethyl starch 130\/0.4 on renal function in surgical patients. Anesthesiology. 2013;118:387\u201394.","journal-title":"Anesthesiology"},{"key":"503_CR56","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s00134-012-2472-9","volume":"38","author":"K Reinhart","year":"2012","unstructured":"Reinhart K, Perner A, Sprung CL, Jaeschke R, Schortgen F, Groeneveld ABJ, et al. Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients. Intensive Care Med. 2012;38:368\u201383.","journal-title":"Intensive Care Med"},{"key":"503_CR57","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1186\/cc12805","volume":"17","author":"CJ Wiedermann","year":"2013","unstructured":"Wiedermann CJ, Joannidis M. Concerns about renal safety of HES 130. Crit Care. 2013;17:444.","journal-title":"Crit Care"},{"key":"503_CR58","doi-asserted-by":"crossref","unstructured":"Wiedermann C. Reason for concern. http:\/\/ccforum.com\/content\/17\/4\/444\/comments . Accessed 12 Sept 2013.","DOI":"10.2174\/1871527311312030017"},{"key":"503_CR59","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","volume":"326","author":"J Lexchin","year":"2003","unstructured":"Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326:1167\u201370.","journal-title":"BMJ"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-014-0503-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T04:08:35Z","timestamp":1565237315000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-014-0503-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,5]]},"references-count":59,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["503"],"URL":"https:\/\/doi.org\/10.1007\/s00508-014-0503-y","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,5]]}}}